Legislative efforts and a Trump administration initiative could lead in the near future to Medicare beneficiary access to ...

In their zeal to “Make America Healthy Again,” Trump administration officials are making statements that some advocacy and ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

The stock of Eli Lilly and Company was up in early trading on Aug. 4 amid reports that Medicare may soon cover its weight-loss medications. This could significantly boost the affordability of Eli ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...